CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Controlled release delivery mechanism helps in delivering a pharmaceutical active compound or drug over an extended period of time, from hours to days. It offers several advantages over conventional drug delivery such as reduced dosing frequency, better therapeutic effectiveness and lower side effects. Factors such as growing prevalence of chronic diseases, rising geriatric population, increasing R&D investments by major players and technological advancements can drive the market growth. However, high costs associated with developing controlled release products and stringent regulatory approval process can pose challenges for the market players.

Market Dynamics:

Global controlled release drug delivery market growth is driven by rising prevalence of chronic diseases such as diabetes, cancer and cardiovascular diseases. According to the WHO, chronic diseases accounted for over 70% deaths worldwide in 2020. Controlled release drugs help in better management of chronic conditions through constant drug levels in the body over an extended time period. Growing geriatric population prone to chronic illnesses can also drive the market growth. However, high costs associated with developing controlled release formulations and long duration of clinical trials can hamper the market growth. Technological advancements in controlled release drug delivery mechanisms, growing preference for long-acting pharmaceuticals, and focus on developing specialty drugs for orphan diseases can offer growth opportunities for market players.

Key features of the study:

• This report provides in-depth analysis of the global controlled release drug delivery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global controlled release drug delivery market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Depomed, Coating Place, Corium, and Johnson and Johnson
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global controlled release drug delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global controlled release drug delivery market.

Detailed Segmentation-

• By Technology
  
  • Wurster Technique
  • Coacervation
  • Micro Encapsulation
  • Transdermal
  • Targeted Delivery
  • Others
• By Therapeutic Area
  
  • Infectious Diseases
  • Oncology
  • Cardiology
  • Neurology
  • Autoimmune Diseases
  • Others
    
•   By Application
  • Metered Dose Inhalers
  • Injectables
  • Infusion Pumps
  • Drug Eluting Stents
  • Others
•  By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:         
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Orbis Biosciences, Inc.
  • Merck and Co., Inc.
  • Alkermes plc
  • Johnson and Johnson
  • Coating Place, Inc.
  • Corium International, Inc.
  • Depomed, Inc.
  • Pfizer, Inc
  • Aradigm Corporation
  • Abbott Laboratories
  • Roche Holdings AG
  • AstraZeneca
  • Baxter International Inc
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company